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Gene delivery using human cord blood–derived CD34cells used for organ regeneration after untreatable damage,
into inflamed glomeruli in NOD/SCID mice. and several stem cells (or progenitor cells), such as endo-
Background. Bone marrow reconstitution using genetically-
thelial stem cells [1] and neural stem cells [2] have beenmodified hematopoietic stem cells has been reported to confer
resistance to inflammation and prevent renal injury in glomeru- discovered. Following the progression of this field of
lonephritis. Although this strategy has potentials for clinical research, the potential for stem cell therapy has increased
use, taking hematopoietic stem cells from bone marrow is and several therapeutic benefits have already been re-highly stressful for patients. In this regard, umbilical cord blood
ported [3, 4]. Although this approach was originallymay be a useful alternative and, therefore, we focused on their
suitability as a source of hematopoietic stem cells for trans- investigated for fatal or hereditary diseases, we have
plantation-based therapy for glomerulonephritis. proposed that inflammatory diseases such as glomerulo-
Methods. CD34 cells were obtained from human umbilical
nephritis are also candidates for transplantation-basedcord blood, retrovirally transduced with human -glucuroni-
dase (HBG) gene, and transplanted into nonobese diabetic/ gene therapy using hematopoietic stem cells [5]. We used
severe combined immunodeficiency (NOD/SCID) mice. After bone marrow–derived cells as a vehicle to deliver anti-
confirming the successful chimerism, these mice were treated
inflammatory molecules into inflamed glomeruli [6, 7].with lipopolysaccharide (LPS), and local HBG expression in
In the ex vivo differentiation system, bone marrow cellsglomeruli was examined using immunohistochemical analysis,
HBG bioassay, and Western blot analysis. were differentiated ex vivo to express ligands of adhesion
Results. Clonogenic assay showed that 88.4  5.9% burst- molecules and acquire the potential to be recruited toforming unit-erythroid (BFU-E), 79.7 11.4% in colony-form-
the inflamed site, and were adenovirally transfected withing unit-macrophage (CFU-M), and 81.1  14.1% in colony-
forming unit-granulocyte (CFU-G), respectively, possessed the a foreign gene followed by transfusion to the affected
transgene after transfection, suggesting that precommited cells subjects. These cells may deliver anti-inflammatory cyto-
were susceptible to retroviral infection. Flow cytometric analy-
kines into inflamed glomeruli [8]. In the in vivo differenti-sis revealed that 24.1  14.5% of bone marrow cells in these
ation system, bone marrow cells were genetically modi-chimera mice expressed human lymphocyte antigen (HLA) 8
weeks after transplantation. Also, clonogenic assay showed fied using retrovirus and transplanted to the affected
that a sustained engraftment of human hematopoietic cells subjects before differentiation so that they may retainexpressed HBG. CD14-positive cells were recruited into the
the potential for self-renewal, as well as differentiation,glomeruli upon LPS treatment and they secreted bioactive
HBG, suggesting that cord blood–derived CD34cells may dif- in vivo [7]. Both systems were able to prove the therapeu-
ferentiate into monocyte lineage while maintaining the expres- tic benefit of anti-glomerular basement membrane (anti-
sion of the transgene.
GBM) nephritis in mice [6, 7]. These strategies haveConclusion. These data indicate that umbilical cord blood
cells can be utilized as a source of hematopoietic stem cells several advantages over the previous glomerulus-tar-
for the transplantation-based therapy of glomerulonephritis. geted gene delivery systems (i.e., use of peripheral ves-
sels for administration, longer therapeutic time window,
and possibly no immunoreaction due to autologous
Recently, stem cell research has attracted considerable
transfer) and suggest that bone marrow–derived cellsattention from many researchers because it could be
can be utilized for therapeutic intervention to treat local
inflammation.
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As a next step toward clinical application, we soughtulonephritis.
a different source of hematopoietic stem cells other than
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In this regard, umbilical cord blood cells may be a useful sity School of Medicine (Tokyo, Japan) from breeding
alternative because: (1) a substantial amount of blood pairs purchased from Jackson Laboratory (Bar Harbor,
(about 100 mL from each delivery [9]) may be corrected ME, USA). Animals were housed in a positive airflow
without pain and risk to mother or infant; (2) they con- ventilated rack and bred and maintained under specific
tain a significantly higher number of hematopoietic pro- pathogen-free conditions.
genitor cells when compared with adult peripheral blood
Establishment of chimera mice[10]; (3) lower incidence and severity of graft versus host
disease (GVHD) after transplantation occurs due to the Human umbilical cord blood samples were obtained,
immature immune system [10]; and (4) recently, large- with informed consent, from placentas of full-term nor-
scale banks of cord blood have been developed or are mal newborn infants. After isolation of mononuclear
being considered throughout world. We, therefore, ex- cells from cord blood by density gradient centrifugation
amined their suitability as a source of hematopoietic with NicoprepTM 1.077 (Nycomed Pharma AS, Oslo, Nor-
stem cells for transplantation-based gene therapy for way), CD34 cells were obtained from mononuclear cells
inflammatory diseases. by magnetic bead separation (Dynal CD34 Progenitor
To monitor the behavior of human cells in vivo, a Cell Selection System; Dynal, Lake Success, NY, USA)
bone marrow repopulating system using the nonobese dia- according to the manufacturer’s instructions. These cells
betic/severe combined immunodeficiency (NOD/SCID) were suspended in MyeloCult H5100 (StemCell Tech-
mouse was applied. NOD/SCID mice are characterized nologies, Inc., Vancouver, British Columbia, Canada)
by a functional deficit of natural killer cells, absence of with penicillin G (100 U/mL), streptomycin (100g/mL),
circulating complement, and defects in the differentia- and amphotericin B (0.25 g/mL) supplemented with
tion and function of antigen-presenting cells (APC), as 200 units/mL human interleukin-6 (IL-6) (Kirin Brewery
well as an absence of T and B cell functions, facilitating Co., Ltd., Tokyo, Japan), and 100 ng/mL human stem
reconstitution with human hematopoietic cells [11, 12]. cell factor (mSCF) (Kirin Brewery Co., Ltd.), Flt-3/Flk-2
Using transplantation techniques, chimera mice, which ligand (100 ng/mL; R & D Systems, Minneapolis, MN,
have a mouse body with a human hematopoietic system, USA), human thrombopoietin (10 ng/mL; Kirin Brewery
may be established. Co., Ltd.). After cultivation in a humidified atmosphere
In this study, we report that umbilical cord blood cells of 5% CO2 at a concentration of 1  106 cells/mL for 24may be a useful alternative as a source of hematopoietic hours, the bone marrow cells were transfected with the
stem cells for transplantation-based gene therapy to treat human HBG gene via a retrovirus as described later.
inflammatory diseases such as glomerulonephritis. NOD/SCID mice were prepared for transplantation with
a sublethal dose of irradiation (3.5 Gy). Genetically-
METHODS modified CD34 cells (5  104/20 g body weight) were
infused into recipient mice via the tail vein once dailyExperimental Design
for 4 consecutive days. Bone marrow cells were freshlyCD34 cells were obtained from human cord blood
prepared for each injection.and retrovirally transfected with human -glucuronidase
(HBG) as a marker. Successful transfection into predif- Recombinant retrovirus preparation and infection
ferentiated cells was confirmed by clonogenic assay.
CD34 cells were transduced with HBG via a retrovi-These cells were transplanted into NOD/SCID mice, and
rus using a centrifuge method [14]. wCRIP packaging8 weeks later successful chimerism was again confirmed
cells [15] producing an MFG-GC vector (1  106 cfu/by clonogenic assay and flow cytometric analysis. Since
mL) expression of HBG were constructed as describedwe found that LPS induced adhesion molecules even in
before [16]. A retroviral vector–containing supernatantthe glomeruli of NOD/SCID mice (data not shown),
was collected from confluent monolayers of these pack-these chimera mice received 25 g LPS purified from
aging cells grown in Dulbecco’s modified Eagle’s me-Klebsiella O3 [13] or saline as a control for 7 days. Tissue
dium (DMEM) with 10% calf serum (CS) (Gibco/BRL,specimens were subjected to immunohistochemical anal-
Grand Island, NY, USA). These supernatants were fil-ysis on human CD14 and HBG to confirm that the trans-
tered (0.45 m) and centrifuged at 14,000 g for 2 hoursplanted premature cells may differentiate into monocyte
at 4C to concentrate the virus [17], followed by resus-lineage cells at the recruited site and those cells still
pension in one-tenth the volume of culture medium.express transgene. HBG bioactivity and Western blot
After pre-stimulation with IL-6, hSCF, thrombopoietin,analysis of isolated glomeruli were also compared be-
and Flt-3/Flk-2 ligand for 24 hours, CD34 cells (5.0 tween LPS-treated and saline-treated mice.
104/mL culture medium) were transferred into a round-
Animals bottomed tube (Falcon #2051, Franklin Lakes, NJ, USA),
which was coated with a recombinant human fibronectinA breeding colony of NOD/SCID mice was estab-
lished at the laboratory animal center of the Jikei Univer- fragment CH-296 (Takara Shuzo Co., Ltd., Shiga, Japan)
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[18], mixed with the same amount of concentrated retro- Two-color immunofluorescent staining
viral vector and 8 g/mL polybrene and centrifuged at Each specimen was embedded in optimal cutting tem-
1500 g at 20C for 2 hours once daily for 3 days [14]. perature (OCT) compound (Miles Scientific, Naperville,
Freshly prepared retroviral vector–containing superna- IL, USA) and quickly frozen in liquid nitrogen. Cryostat
tant was used for each period of infection. Between cen- sections (6 m) were dried and fixed with acetone for 15
trifugations, the cells were incubated with culture medium minutes. After blocking the endogenous biotin with an
in the presence of IL-6, hSCF, thrombopoietin, and Flt-3/ avidin/biotin blocking kit (Vector Laboratories, Burl-
Flk-2 ligand without transfer from the centrifuge tube. ingame, CA, USA), the sections were incubated with
After the third centrifugation, CD34 cells were washed sheep anti-human CD14 (Genzyme, Cambridge, MA,
and resuspended in phosphate-buffered saline (PBS) for USA) and goat anti-human HBG (a kind gift from Dr.
William S. Sly) at 4C overnight and biotinylated donkeytransplantation.
anti-sheep IgG (Chemicon, Temecula, CA, USA) for 2
Fluorescence cytometry hours at 37C. After rinsing in PBS, the sections were
incubated with Alexa Fluor rabbit anti-goat IgG (HL)Bone marrow cells were harvested from chimera mice
conjugate (Molecular Probes, Leiden, The Netherlands)8 weeks after transplantation and incubated with mouse
and FITC-streptavidin (Becton Dickinson, Franklinimmunoglobulin G (IgG) and fluorescein isothiocya-
Lakes, NJ, USA). The sections were mounted in p-phe-nate (FITC)-conjugated anti-human HLA ABC antigen
nylenediamine (PD)-PBS-glycine and observed under a(Sigma, St. Louis, MO, USA) for 30 minutes and 60 min-
fluorescence photomicroscope. Pictures were taken usingutes, respectively, at 4C. Samples were analyzed on a
an autoexposure camera (Zeiss, Thornwood, NY, USA).flow cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA). Four chimera mice were analyzed individually. HBG enzymatic activity of isolated glomeruli
As a positive control, mononuclear cells from healthy
HBG bioactivity of isolated glomeruli was assayedvolunteers were also subjected to flow cytometric analysis.
as described [22]. Briefly, glomeruli from chimera mice
transplanted with LPS or saline treatment were isolatedClonogenic assay for transduced CD34 cells
and homogenized in distilled water using a glass homoge-Clonogenic assay was performed as previously de-
nizer. The homogenates were spun at 14,000g for 10scribed [19]. In brief, transduced CD34 cells were plated
minutes at 4C. The clear supernatant was assayed fluo-at a concentration of 1  103 cells/mL in MethoCult
rometrically for HBG activity with the synthetic fluoro-GF H4434V (methylcellulose-containing medium with
genic substrate 4-methylumbelliferyl -D-glucuronidaseerythropoietin, stem cell factor, GM-CSF, and IL-3)
(Sigma). After incubation of each sample with the sub-
(StemCell Technologies, Inc.). After 14 days, CFU-G,
strate for 30 minutes at 37C, reactions were terminated
CFU-M, and BFU-E were selected and DNA was ex-
by the addition of 0.17mol/L glycine-carbonate buffer
tracted following a previously published method [20]. (pH 10.4). The 4-methylumbelliferone (4-MU) that had
The yield of DNA was monitored by human-specific 2 formed was measured fluorometrically. Units of HBG
microgloblin polymerase chain reaction (PCR) [21]. To activity are defined as nanomoles 4-MU produced/hr/mg
amplify the HBG cDNA sequence, PCR was carried out protein. Protein concentration was determined with a
on genomic DNA samples in a final volume of 100 L. bicinchorinic acid (BCA) kit (Pierce, Rockford, IL, USA).
The primers used for PCR were 5-GAT GGT GAT
CGC TCA CAC CA-3 and 5-CGG TGA CTG TTC Immunoprecipitation of human HBG
AGT CAT GA-3, which amplify part of the HBG Since measurements of HBG enzymatic activity were
cDNA sequence. The reaction mixture contained 250 made both of total HBG activity representing the endog-
mol/L of each desoxynucleoside triphosphate (dNTP), enous murine HBG activity and any human HBG activity
2.5 units of Amplitaq Gold (Perkin Elmer, Foster City, resulting from gene transfer, immunoprecipitation of hu-
CA, USA), 2.5 mmol/L MgCl2, and 0.5 mol/L of each man HBG was performed to estimate the human HBG
primer in Amplitaq buffer. Thermal cycling was per- activity only. Each sample was divided into two identical
formed on Takara PCR Thermal cycler MP (Takara aliquots and the human HBG was immunoprecipitated
Shuzo Co., Ltd.) as follows: 95C for 5 minutes for initial from one of each pair. Ten micrograms of protein of
denaturing, followed by 63 cycles of 94C for 1 minute, each homogenate were mixed with either 10 L of anti-
60C for 1 minute, and 60C for 5 minutes for the final human HBG or distilled water, and shaken at 4C for 1
extension cycle. After electrophoresis in a 2% agarose hour. Twenty five microliters of protein A sepharose 4
gel, the amplified products were visualized with ethidium fast flow (Amersham Pharmacia Biotech, Buckingham-
bromide staining. Experiments were performed in qua- shire, UK) was then added to each of the samples, which
were inverted overnight at 4C. Samples were spun atdruplicate and representative pictures are shown.
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12,000g for 2 minutes and supernatant removed for mea-
surement of HBG enzymatic activity.
Western blot analysis
Western blot analysis was performed to measure the
secretion of HBG from recruited human CD14 cells in
the glomeruli as described [6]. Briefly, homogenates of
isolated glomeruli (2 g) from LPS-treated and saline-
treated mice were subjected to electrophoresis in a
12.5% sodium dodecyl sulfate-polyacrylamide gel and
then transferred to nitrocellulose membrane. The mem-
brane was blocked with 5% dried milk, 0.1% Tween
20, PBS, and incubated with anti-human HBG antibody
(1000). It was then incubated with rabbit anti-gout im-
munoglobulin horseradish peroxidase conjugate (Cosmo
Bio, Tokyo, Japan). Antigen-antibody complexes were
visualized by chemiluminescence reagents (Amersham
Pharmacia Biotech).
Analysis of proteinuria and serum creatinine
The concentration of albumin in urine was measured
by single radial immunodiffusion (SRID) [23] using a
specific antibody for mouse albumin [24]. Briefly, sam-
ples were applied to a 1% agarose gel containing anti-
mouse albumin and incubated for 48 hours. The diame- Fig. 1. Susceptibility of hematopoietic stem cells to retroviral transfec-
tion. Human cord blood–derived CD34 cells were transfected withters of the expressed rings on the gel were measured
human  glucuronidase (HBG) and cultured with erythropoietin, stemand their concentrations were assessed by comparison cell factor, granulocyte macrophage colony stimulating factor (GM-
with a standard curve. Concentration of plasma creati- CSF), and interleukin-3 (IL-3) for 14 days. Well-isolated single colonies
of BFU-E, CFU-M, and CFU-G were picked up and DNA was extractednine was measured using the Vision analyzer kit (Abbott
and processed for PCR on human -glucuronidase (HBG). The yieldLaboratories, North Chicago, IL, USA), which is based of DNA was monitored by human specific 2 microgloblin (MG). After
on the Jeffe reaction. electrophoresis in a 2% agarose gel, the amplified products were visual-
ized with ethidium bromide staining. Experiments were performed in
quadruplicate and representative pictures are shown.Statistical analysis
Data are expressed as mean  SE. Statistical analysis
was performed using the two-sample t test to compare data
in different groups. P  0.05 was found to be significant. are susceptible to retroviral transfection in the precom-
mited form.
RESULTS Establishment of chimera mouse that has mouse body
Susceptibility of CD34 cord blood cells to with human hematopoietic system
retroviral transfection To establish the chimera mouse, the hematopoietic
To examine the efficacy of CD34 cord blood cells systems were exchanged for human cells, and HBG-
to retroviral transfection, CD34 cells were established transfected CD34 cells were transplanted to NOD/
from freshly obtained human cord blood cells and retro- SCID mice. After 8 weeks, bone marrow cells from these
virally transfected with the human HBG gene, using mice were subjected to flow cytometric analysis on hu-
centrifugation methods with concentrated viral superna- man HLA ABC antigen. As shown in Figure 2A, 24.1 
tant. These cells were cultured in MethoCult GF H4434V 14.5% of bone marrow cells in these chimera mice ex-
for 14 days and DNA from each colony was subjected pressed human HLA ABC antigen, showing successful
to PCR on the HBG gene. As shown in Figure 1, three chimerism in these mice. To confirm that these reconsti-
different lineages of hematopoietic cell possessed the tuted bone marrow cells still maintained the transgene
transgene (88.4  5.9% in BFU-E, 79.7  11.4% in clonogenic assay was also performed on HBG. As shown
CFU-E, and 81.1  14.1% in CFU-G, respectively), and in Figure 2B, the cells from these marrows still possessed
there were no significant differences between lineages, the transgene (31.4  10.8% in BFU-E, 38.9  18.9%
in CFU-E, and 33.8  19.9% in CFU-G, respectively),suggesting that CD34 cells from human cord blood cells
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Fig. 2. Establishment of chimera mice. (A )
Bone marrow of NOD/SCID mice was recon-
stituted with genetically-engineered human
CD34 cells using a transplantation-based
method. Eight weeks later, bone marrow was
harvested from these mice and incubated with
fluoroscein isothiocyanate (FITC)-conjugated
human HLA ABC antibody. Ten thousand
cells were subjected to flow cytometric analy-
sis (center panel). As a control, bone marrow
cells from NOD/SCID mice without bone
marrow reconstitution (left panel), and human
mononuclear cells from healthy volunteers
(right panel), were also subjected to the same
procedure. (B ) Harvested bone marrow cells
were also subjected to clonogenic assay on
the human  glucuronidase (HBG) gene to
confirm that the reconstituted bone marrow
still possessed the transgene. Four mice per
group were analyzed individually and repre-
sentative data are shown.
showing a sustained engraftment of human hematopoi- HBG. The total HBG enzymatic activity in isolated glo-
meruli was not significantly elevated by LPS treatmentetic cells expressing the HBG gene.
(716.0  68.8 nmol/hr/mg in saline-treated mice vs.
Delivery into inflamed site by in vivo differentiated 1085.9  137.5 nmol/hr/mg in LPS-treated mice; P 	
human cells 0.0821) (Fig. 3B). However, transplanted human HBG
activity, which was estimated by subtraction of endoge-Since Verstegan et al [25] previously reported that
nous murine HBG activity from total HBG, was signifi-human monocytes may spontaneously grow out in the
cantly elevated by LPS treatment (148.1  52.0 nmol/SCID mice after transplantation with unfractionated hu-
hr/mg in saline-treated mice vs. 574.8  102.7 nmol/man cord blood cells, we speculated that transplanted
hr/mg in LPS-treated mice; P 	 0.0041). Furthermore,human CD34 cells may differentiate into mononuclear
Western blot analysis revealed that isolated glomerulicells and effectively deliver transgene into inflamed glo-
meruli. Chimera mice were treated with LPS or saline from LPS-treated chimera mice contained higher amount
of HBG protein compared with control chimera miceonce daily for 7 days and subjected to immmunohisto-
chemical analysis, HBG enzymatic assay, and Western (Fig. 3C). Together, these data suggested that umbilical
cord blood–derived CD34cells might differentiate intoblot analysis of HBG expression. At day 7, kidneys were
obtained from these mice and tissue sections were monocyte lineage cells while maintaining the expression
of the foreign gene.stained with human CD14 and HBG. As shown in Figure
3A, CD14 cells were detected in the glomeruli upon Although native macrophages may influence the be-
havior of donor macrophages, only a negligible numberLPS treatment, and 19.3  4.4% of those cells secreted
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(ICAM-1) expression in the glomeruli without competi-
tion with native macrophages, by which the significance
of transgene activity might be enhanced. On the other
hand, recruitment of transplanted cells into glomeruli
might affect renal function and, therefore, renal function
after LPS treatment was examined in chimera mice. Both
urine albumin and serum creatinine levels were under
detectable level (the lowest detectable concentrations of
albumin and creatinine are 20 mg/mL and 0.3 mg/dL,
respectively), suggesting that accumulation of exogenous
human CD14 cells, per se, did not affect renal function
in chimera mice.
DISCUSSION
Transplantation-based gene therapy has been pro-
posed as a novel therapeutic strategy for chronic in-
flammatory diseases such as glomerulonephritis [5]. This
approach is based on the fact that inflammatory cells such
as macrophages and neutrophils are capable of being
recruited to and activated at the inflamed glomeruli and,
therefore, genetic manipulation of bone marrow–derived
cells or bone marrow, per se, using transplantation-based
technology may modify inflammation. We previously re-
ported that bone marrow reconstitution using geneti-
cally-modified hematopoietic progenitor cells to supply
anti-inflammatory mononuclear cells to inflamed glo-
meruli confer resistance against glomerular inflamma-
tion [7]. As the next step toward the clinical use, we
investigated the suitability of human umbilical cord
blood as a source of hematopoietic stem cells, which may
reduce the risks to patients, and showed that CD34 cells
Fig. 3. Gene delivery using monocytes derived from human cord blood. from human cord blood may reconstitute bone marrow;
Eight weeks after transplantation, chimera mice were treated with LPS
these cells may differentiate into monocyte lineage cells,to induce ICAM-1 expression in the glomeruli, or saline as a control.
(A ) Immunohistochemical analysis. Kidney sections from chimera mice which may deliver foreign genes into inflamed glomeruli.
with LPS (left) or saline (right) treatment were subjected to two-color In addition to fewer risks to the mother and infant,
immunofluorescent staining on human CD14 and human  glucuroni-
umbilical cord blood cells have several advantages as adase (HBG). Green fluorescence represents CD14 positive cells and
red fluorescence represents secreted human HBG. (B ) HBG enzymatic source of hematopoietic stem cells for clinical allogeneic
activity of isolated glomeruli. Glomeruli from LPS-treated or saline- transplantation. For example, umbilical cord blood cells
treated mice were isolated by sieving method and the homogenates
can be cryopreserved and easily shipped and thawed forwere subjected to HBG bioassay. Symbols are: () total HBG activity;
( ) HBG activity remaining after immunoprecipitation with anti- use on demand, eliminating delays and uncertainties that
human HBG antibody. (C ) Secretion of human HBG from recruited presently complicate marrow collection from unrelated
cells. Two microgram protein of isolated glomeruli from LPS-treated
donors [29]. The amplification of allogeneic responsesand saline-treated mice were subjected to Western blot analysis of
human HBG expression. As a control, glomeruli from wild type mice by neonatal T lymphocytes has been shown to be less
treated with LPS or saline were also examined under the same protocol. than that of adult T cells, which may underlie umbilical
M is molecular weight marker.
cord blood reduced graft-versus-host reactivity [30, 31].
Although these advantages strengthen the rational of its
clinical use, there are several obstacles to be overcome.
First, the efficacy of retroviral transfection is quite lowof native macrophages could be detected in the glomeruli
for human stem cells compared to mouse stem cells [32].of the NOD/SCID mice treated with LPS (data not
We tried several different methods and finally concludedshown), probably because the number of native macro-
that the most efficient transfection was done by a centrif-phages in NOD/SCID mice are small [26] and are func-
ugation method [14] using recombinant human fibro-tionally immature [27], especially when the response to
nectin fragment CH-286–coated tubes [18] with concen-LPS is impaired [28]. Therefore, donor macrophages may
occupy the area of intercellular adhesion molecule-1 trated viral supernatant [17]. This modification resulted
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in the highest efficacy among our retrovirus-based trans- whether bone marrow progenitor cells may maintain this
regulation during the differentiation in our laboratory.duction attempt. However, it may not be sufficient for
Recently, stem cell therapy has advanced with thetherapeutic intervention, especially if the antagonist is
discovery of several stem cells. We previously reported,used to cancel the effect of inflammatory cytokines. In
using transplantation technology, that mesangial progen-terms of clinical application, further modification is
itor cells might exist in bone marrow cells [44], mostneeded. In this regard, attempts to establish a novel
likely in the fraction of mesenchymal stem cells becausevector system, such as lentivirus vectors based on the
donor cells did not differentiate into residential mesan-human immunodeficiency virus, have been made [33].
gial cells when bone marrow was transplanted after elim-The use of these vectors, however, raises concerns about
ination of mesenchymal stem cells by culture in IL-3,their safety, which must be completely cleared before
IL-6, and SCF for 72 hours [7]. Therefore, we have pro-clinical use. Another approach to overcome the low gene
posed two different therapeutic strategies for glomerulartransfection efficacy is selection or expansion of trans-
diseases, depending upon whether to differentiate bonefected stem cells ex vivo [34, 35] or in vivo [36, 37].
marrow stem cells into mesenchymal or hematopoieticFor instance, cotransfection with a gene that confers a
stem cells. In the case of diseases which need reconstitu-reversible growth advantage in the presence of a syn-
tion of residential glomerular cells, such as congenitalthetic drug may achieve a marked and sustained expan-
enzyme deficiency diseases, mesenchymal stem cellssion of transfected hematopoetic cells [38]. These trials
should be transplanted and, in contrast, diseases whichmay improve the low transduction efficacy of human
need foreign cytokines and growth factors, such as glo-stem cells.
merulonephritis, hematopoietic stem cells may used forOnly 5  106 cells could be collected from 50 mL
gene delivery. Although we are still in the learning phase,umbilical cord blood cells in our method; it has been
because umbilical cord blood has been considered as areported that the safest threshold needed for en-
viable source of hematopoietic and mesenchymal stemgraftment of autologous peripheral blood stem cells
cells [45], our success in this report allows us to proceedshould be 7.8  106 CD34 cells/kg body weight [39],
to the next step in the long avenue of research aimedhowever, suggesting that cord blood samples harvested
to provide stress-free, tailor-made stem cell therapy forfrom one placenta may be insufficient and ex vivo expan-
glomerular disease.sion of umbilical cord blood progenitor cells may be
necessary to engraft larger patients. For this purpose,
ACKNOWLEDGMENTSBroxmeyer et al [40] reported that umbilical cord blood
We thank Dr. William S. Sly (St. Louis University) for providingcolony forming unit-granulocyte macrophage (CFU-
us with the anti-human HBG antibody, Ms. Murata for assisting withGM) progenitor cells may be increased in vitro by 8- to
immunohistochemical analysis, and Ms. Agawa for assisting with flow
11-fold in the presence of stem cell factor (SCF) and cytometric analysis. This work was supported by a grant from the
Ministry of Health and Welfare of Japan; the Bio-Venture Researchgranulocyte macrophage colony stimulating factor (GM-
Fund Project Aid grant from the Ministry of Education, Science andCSF). CD34 cells isolated from cord blood have also
Culture of Japan; and Sankyo Foundation of Life Science.
been reported to be able to expand in the presence of
Reprint requests to Takashi Yokoo, M.D., Ph.D., Department ofIL-11 and granulocyte colony stimulating factor (G-CSF)
Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-to a higher degree compared with those from human
Shimbashi, Minato-ku, Tokyo, Japan.
adult bone marrow (80-fold) [41], suggesting a significant E-mail: tyokoo@jikei.ac.jp
level of self-renewal capacity for umbilical cord blood
stem cells. Further study is necessary to show ex vivo REFERENCES
expansion of umbilical cord blood progenitor cells to
1. Asahara T, Murohara T, Sullivan A, et al: Isolation of putative
accelerate hematopoietic reconstitution. progenitor endothelial cells for angiogenesis. Science 275:964–967,
1997Unfractionated marrow cells were used to reconstitute
2. Bjornson CR, Rietze RL, Reynolds BA, et al: Turning brainbone marrow and, therefore, cells other than monocyte- into blood: A hematopoietic fate adopted by adult neural stem
lineage cells possess the foreign gene, which may cause cells in vivo. Science 283:534–537, 1999
3. Gussoni E, Soneoka Y, Strickland CD, et al: Dystrophin expres-an unpredictable effect in a nontargeted organ. Hence,
sion in the mdx mouse restored by stem cell transplantation. Naturean on/off switching system, in which mononuclear lin- 401:390–394, 1999
eage cells only are activated exclusively at the inflamed 4. Hou Z, Nguyen Q, Frenkel B, et al: Osteoblast-specific gene
expression after transplantation of marrow cells: Implication forsite, will be required. We recently succeeded in inflamed
skeletal gene therapy. Proc Natl Acad Sci USA 96:7294–7299, 1999site-specific activation of terminally differentiated- 5. Yokoo T, Ohashi T: Transplantation-based gene therapy for in-
monocyte lineage cells using an IL-1 promoter com- flammatory diseases: Focus on glomerulonephritis. Curr Gene Ther
1:227–235, 2001bined with a Cre/loxP system [42], so that transgene
6. Yokoo T, Ohashi T, Utsunomiya Y, et al: Prophylaxis of antibody-
could be induced in the cells and the environment where induced acute glomerulonephritis with genetically modified bone
marrow-derived vehicle cells. Hum Gene Ther 10:2673–2678, 1999IL-1 was produced [43]. Currently it is being examined
Yokoo et al: Gene delivery into glomeruli using human cord blood cells 109
7. Yokoo T, Ohashi T, Utsunomiya Y, et al: Genetically modified SCID mice: Evidence for accessory cell involvement in expansion
of immature CD32CD38
 cells. Blood 91:1966–1976, 1998bone marrow continuously supplies anti-inflammatory cells and
26. Shibata S, Asano T, Noguchi A, et al: Peritoneal macrophagessuppresses renal injury in mouse Goodpasture syndrome. Blood
play an important role in eliminating human cells from severe98:57–64, 2001
combined immunodeficient mice transplanted with human periph-8. Yokoo T, Utsunomiya Y, Ohashi T, et al: Inflamed site-specific
eral blood lymphocytes. Immunology 98:524–532, 1998gene delivery using bone marrow-derived CD11bCD18 vehicle
27. Rosmalen JGM, Homo-Delarche F, Durant S, et al: Islet abnor-cells in mice. Hum Gene Ther 9:1731–1738, 1998
malities associated with an early influx of dendritic cells and macro-9. Broxmeyer HE, Gluckman E, Auerbach A, et al: Human umbili-
phages in NOD and NODscid mice. Lab Invest 80:769–777, 2000cal cord blood: A clinically useful source of transplantable hemato-
28. Shultz LD, Schweitzer PA, Christianson SW, et al: Multiplepoietic stem/progenitor cells. Int J Cell Cloning 8:76–91, 1990
defects in innate and adaptive immunologic function in NOD/10. Cairo MS, Wagner JE: Placental and/or umbilical cord blood: An
LtSz-scid mice. J Immunol 154:180–191, 1995alternative source of hematopoietic stem cells for transplantation. 29. Laughlin MJ: Umbilical cord blood for allogenieic transplantation
Blood 90:4665–4678, 1997 in children and adults. Bone Marrow Transplant 27:1–6, 2001
11. Shultz LD, Schweitzer PA, Christianson SW, et al: Multiple 30. Chalmers IM, Janossy G, Contreras M, Navarrete C: Intracellu-
defects in innate and adaptive immunologic function in NOD/LtSz- lar cytokine profile of cord and adult blood lymphocytes. Blood
scid mice. J Immunol 154:180–191, 1995 92:11–14, 1998
12. Larochelle A, Vormoor J, Hanenberg H, et al: Identification of 31. Kadereit S, Mohammad SF, Miller RE, et al: Reduced NFAT1
primitive human hematopoietic cells capable of repopulating protein expression in human umbilical cord blood T lymphocytes.
NOD/SCID mouse bone marrow: Implication for gene therapy. Blood 94:3101–3107, 1999
Nat Med 2:1329–1337, 1996 32. Hanazono Y, Dunbar CE: Hematopoietic Cell Transplantation
13. Yokochi T, Fukada M, Kawai M, et al: Novel adjuvant action of (2nd edition), edited by Forman SJ, Malden, MA, Blackwell Sci-
lipopolysaccharides that possess mannose homopolysaccharides as ence, 1999, pp 89–96
33. Buchschacher GL, Wang-Staal F: Development of lentiviralo-specific polysaccharides on immune response to nonimmuno-
vectors for gene therapy for human diseases. Blood 15:2499–2504,genic autoantigens in mice. Infect Immun 60:4953–4956, 1992
200014. Bahnson AB, Dunigan JT, Baysal BE, et al: Centrifugal enhance-
34. Persons DA, Allay JA, Riberdy JM, et al: Use of the greenment of retroviral mediated gene transfer. J Virol Methods 54:131–
fluorescent protein as a maker to identify and track genetically143, 1995
modified hematopoietic cells. Nat Med 4:1201–1205, 199815. Danos O, Mulligan RC: Safe and efficient generation of recombi-
35. Phillips K, Gentry T, McCowage G, et al: Cell-surface markersnant retrovirus with amphotropic and ecotropic host ranges. Proc
for assessing gene transfer into human hematopoietic cells. NatAcad Sci USA 85:6460–6464, 1988
Med 2:1154–1156, 199616. Ohashi T, Boggs S, Robbins P, et al: Efficient transfer and sus-
36. Iwata M, Nunoi H, Matsuda I, et al: Drug-selected completetained high expression of the human glucocerebrosidase gene in
restoration of superoxide generation in Epstein-Barr virus-trans-mice and their functional macrophages following transplantation
formed B cells from p47phox-deficient chronic granulomatous dis-of bone marrow transduced by a retroviral vector. Proc Natl Acad ease patients by using a bicistronic retrovirus vector encoding a
Sci USA 89:11332–11336, 1992 human multi-drug resistance gene (MDR1) and the p47phox gene.
17. Bowles NE, Eisensmith RC, Mohuiddin R, et al: A simple and Hum Genet 103:419–423, 1998
efficient method for the concentration and purification of recombi- 37. Allay JA, Persons DA, Galipeau J, et al: In vivo selection of
nant retrovirus for increased hepatocyte transduction in vivo. Hum retrovirally transduced hematopoietic stem cells. Nat Med 4:1136–
Gene Ther 7:1735–1742, 1996 1143, 1998
18. Hanenberg H, Hashino K, Konishi N, et al: Optimization of 38. Richard RE, Wood B, Zeng H, et al: Expansion of genetically
fibronectin-assisted retroviral gene transfer into human CD34 modified primary human hematopoietic cells using chemical in-
hematopoietic cells. Hum Gene Ther 8:2193–2206, 1997 ducers of dimerization. Blood 95:430–436, 2000
19. Ohashi T, Iizuka S: Sly WS, et al: Efficient and persistent expres- 39. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical
sion of b-glucuronidase gene in CD34 cells from human umbilical estimation of circulating hematopoietic progenitors for autologous
transplantation in cancer patients. Blood 77:400–409, 1991cord blood by retroviral vector. Eur J Haematol 61:235–239, 1998
40. Broxmeyer HE, Hangoc G, Cooper S, et al: Growth characteristics20. Deisseroth AB, Zu Z, Claxton D, et al: Genetic marking shows
and expansion of human umbilical cord blood and estimation ofthat Ph cells present in autologous transplants of chronic myeloge-
its potential for transplantation in adults. Proc Natl Acad Sci USAnous leukemia (CML) contribute to relapse after autologous bone
89:4109–4113, 1992marrow in CML. Blood 83:3068–3076, 1994
41. van de Ven C, Ishizawa L, Law P, Cairo M: IL-11 in combination21. Spence SE, Keller JR, Ruscetti FW, et al: Engraftment of SCID
with steel factor and G-CSF or GM-CSF significantly increasesmice by human bone marrow hematopoietic cells cultured in vitro:
expansion of isolated CD34 cell population from cord bloodAn in vivo model for human gene transfer. Leukemia 9(Suppl 1):
versus adult bone marrow. Exp Hematol 23:1289–1295, 1995S43–S47, 1995
42. Kanegae Y, Lee G, Sato Y, et al: Efficient gene activation in22. Glaser JH, Sly WS: -glucuronidase deficiency mucopolysacchar-
mammalian cells by using recombinant adenovirus expressing site-idosis: Methods for enzymatic diagnosis. J Lab Clin Med 82:969– specific Cre recombinase. Nucleic Acids Res 23:3816–3821, 1995
977, 1973 43. Yokoo T, Ohashi T, Utsunomiya Y, et al: Inflamed glomeruli-
23. Mancini G, Carbonara AO, Heremans JF: Immunochemical specific gene activation using recombinant adenovirus with Cre/
quantitation of antigens by single radial immunodiffusion. Immu- loxP system. J Am Soc Nephrol 11:2330–2337, 2001
nochemistry 2:235–254, 1965 44. Imasawa T, Utsunomiya Y, Kawamura T, et al: The potential of
24. Yumura W, Sugimoto N, Nagasawa R, et al: Age-associated bone marrow-derived cells to differentiate to glomerular mesangial
changes in renal glomeruli of mice. Exp Gerontol 24:237–249, 1989 cells. J Am Soc Nephrol 12:1401–1409, 2001
25. Verstegan MMA, van Hennik PB, Terpstra W, et al: Transplanta- 45. Erices A, Conget P, Minguell JJ: Mesenchymal progenitor cells
in human umbilical cord blood. Br J Haematol 109:235–242, 2000tion of human umbilical cord blood cells in macrophage-depleted
